参考文献：
[1]MOSHFEGHI AA,ROSENFELD PJ,PULIAFITO CA,et al.Systemic bevacizumab(avastin)therapy for neovascular age-related macular degeneration:24-week results of an uncontrolled,open label clinical study[J].Ophthalmology,2006,113(11):1-12.
[2]SLEDGE G,MILLER K,NOVOTNY W,et al.A phase Ⅱ trial of singleangent rhuMAb VEGF(recombinant humanized monoclonal antibody to vascular endothelial cell gowth)in patients with relapsed metastatic breast cancer[J].36th Annual Meeting of the American Society of Clinical Oncology.2000,20(19):3-20
[3]ROSENFELD PJ,MOSHFEGHI AA,PULIAFITO CA.Optical coherence tomography findings after an intravitreal injection of bevacizumab(avastin)for neovascular age-related macular degeneration[J].Ophthal Surg Laser Imag,2005,36(4):331-335.
[4]GEITZENAUER W,MICHELS S,PRAGER F,et al.Early effects of systemic and intravitreal bevacizumab(avastin(R)):therapy for neovascular age-related macular degeneration[J].Klin Monatsbl Augenheilkd,2006,223(10):822-827.
[5]FUNG AE,ROSENFELD PJ,REICHEL E.The international intravitreal bevacizumab safety survey:using the internet to assess drug safety worldwide[J].Br J Ophthalmol,2006,90(11):1344-1349.
[6]NICOLO M,GHIGLIONE D,CALABRIA G.Retinal pigment epithelial tear following intravitreal injection of bevaeizumab(avastin)[J].Eur J Ophthalmol.2006,16(5):770-773.
[7]COSTA RA,JORGE R,CALUCCI D,et al.Intravitreal bevacizumab for choroidal neovascularization caused by AMD(IBeNA study):results of a phase 1 dose-escalation study[J].Invest Ophthalmol Vis Sci,2006,47(10):4569-4578.
[8]LAZIC R,GABRIC N.Intravitreally administered bevacizumab(avastin)in minimally classic and occult choroidal neovascularization secondary to agerelated macular degeneration[J].Graefes Arch Clin Exp Ophthalmol,2007,245(1):68-73.
[9]NGUYEN QD,SHAH S,TATLIPINAR S,et al.Bevacizumab suppresses choroidal neovascularisation caused by pathological myopia[J].Br J ophthalmol,2005,89(10):1368-1370.
[10]LAUD K,SPAIDE RF,FREUND KB,et al.Treatment of choroidal neovascularization in pathologic myopia with intravitreal bevacizumab[J].Retina,2006,26(8):960-963.
[11]SOLIMAN W,LAUD AH,LARSEN M.Resolution of subretinal haemorrhage and fluid after intravitreal bevacizumab in aggressive peripapillary subretinal neovascularization[J].Acta Ophthalmol Scand,2006,84(5):707-708.
[12]TEIXEIRA A,MORAES N,FARAH ME,et al.Choroidal neovascularization treated with intravitreal injection of bevacizumab(avastin)in angioid streaks[J].Acta Ophthalmol Scand,2006,84(6):835-836.
[13]SPAIDE RF,FISHER YL.Intravitreal bevacizumab(avastin)treatment of proliferative diabetic retinopathy complicated by vitreous hemorrhage[J].Retina,2006,26(3):275-278.
[14]AVERY RL,PEARLMAN J,PIERAMICI DJ,et al.Intravitreal bevacizumab(avastin)in the treatment of proliferative diabetic retinopathy[J].Ophthalmol,2006,113(10):1695-1715.
[15]DAVIDORF FH,MOUSER JG,DERICK RJ.Rapid improvement of rubeosis iridis from a single bevacizumab(avastin)injection[J].Retina,2006,26(3):354-356.
[16]SIQUEIKA RC,COSTA RA,SCOTY IU,et al.Intravitreal bevacizumab(avastin)injection associated with regression of retinal neovascularization caused by sickle cell retinopathy[J].Acta Ophthalmol Scand,2006,84(6):834-835.
[17]SHAH PK,NARENDRAN V,TAWANSY KA,et al.Intravitreal bevacizumab(avastin)for post laser anterior segment ischemia in aggressive posterior retinopathy of prematurity[J].Indian J Ophthalmol,2007,55(1):75-76.
[18]BOM AGGIO F,EID FARAH M,MELO GB.Intravitreal bevacizumab for occult choroidal neovascularization with pigment epithelium detachment in age-related macular degeneration[J].Acta Ophthalmol Scand,2006,84(5):713-714.
[19]ITURRALDET D,SPAIDE RF,MEYERLE CB,et al.Intravitreal bevacizumab(avastin)treatment of macular edema in central retinal vein occlusion:a short-term study[J].Retina,2006,26(3):279-284.
[20]MASON JO 3RD,ALBERT MA JR,VAIL R.Intravitreal bevacizumab(avastin)for refractory pseudophakic cystoid macular edema[J].Retina,2006,26(3):356-357.
[21]HARIOGLOU C,KOCP D,NEUBAEWER A,et al.Intravitreal bevacizumab(avastin)therapy for persistent diffuse diabetic macular edema[J].Retina 2006;26(9):999-1005.
[22]HOSSEINI H,NEJABAT M.A potential therapeutic strategy for inhibition of corneal neovascularization with new anti-VEGF agents[J].Med Hypotheses,2007,68(4):779-801.
继续教育试题
选择题：
1．Bevacizumab与VEGF的结合点有：（ ）
A.1个 B.2个 C.3个 D.4个
2．发达国家60岁以上人群首位致盲原因是：（ ）
A.PDR B.AMD C.CRVO D.VH
3.AMD患者中，致盲原因90%是因为：（ ）
A.CNV B.CRVO C.CFT D.VH
4．Bevacizumab是VEGF的单克隆抗体，其大小是：（ ）
A.145kb B.149kb C.157kb D.160kb
5．Bevacizumab最早用于临床是治疗：（ ）
A.AMD B.PDR C.VH D.PED
填空题：
1．玻璃体腔内注射bevacizumab治疗CNV对轻微典型型、 和 短期应用均有效，没有明显的安全性问题。
2．Bevacizumab玻璃体腔内注射有引起一过性幻视或RPE撕裂的报道，因此对伴较大 的AMD患者应慎用。
3．光凝可减少CNV导致的严重视力下降的风险，但对中心凹下、 和 等多种情况无法应用。
简答题：
1．简述Bevacizumab全身用药及玻璃体腔内注射的不良反应。
2．简述Bevacizumab可用于临床那些眼科疾患？
上一页 [1] [2] |
